TransMedics Group, Inc. TMDX
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 727.65M | 668.47M | 635.89M | 605.49M | 566.35M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 727.65M | 668.47M | 635.89M | 605.49M | 566.35M |
| Cost of Revenue | 301.22M | 276.12M | 260.15M | 242.69M | 224.95M |
| Gross Profit | 426.43M | 392.35M | 375.74M | 362.81M | 341.41M |
| SG&A Expenses | 233.59M | 218.27M | 204.53M | 185.17M | 180.63M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 641.20M | 586.86M | 541.45M | 496.91M | 470.40M |
| Operating Income | 86.45M | 81.61M | 94.44M | 108.58M | 95.95M |
| Income Before Tax | 73.62M | 72.55M | 89.33M | 107.52M | 92.88M |
| Income Tax Expenses | -70.83M | -79.15M | -82.59M | -82.77M | 1.11M |
| Earnings from Continuing Operations | 144.45 | 151.70 | 171.92 | 190.29 | 91.77 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 144.45M | 151.70M | 171.92M | 190.29M | 91.77M |
| EBIT | 86.45M | 81.61M | 94.44M | 108.58M | 95.95M |
| EBITDA | 123.86M | 115.63M | 125.35M | 134.47M | 120.55M |
| EPS Basic | 4.21 | 4.43 | 5.03 | 5.58 | 2.71 |
| Normalized Basic EPS | 1.33 | 1.32 | 1.64 | 1.98 | 1.71 |
| EPS Diluted | 3.64 | 3.84 | 4.35 | 4.86 | 2.48 |
| Normalized Diluted EPS | 1.14 | 1.13 | 1.39 | 1.66 | 1.45 |
| Average Basic Shares Outstanding | 137.88M | 137.30M | 136.63M | 135.97M | 135.34M |
| Average Diluted Shares Outstanding | 158.66M | 158.58M | 158.43M | 162.15M | 156.43M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |